MabionCD20 is a monoclonal antibody originally developed by Mabion as a biosimilar candidate to MabThera and Rituxan therapies
Knowledge paper highlights biosimilars, biologics, AI-driven drug discovery and regulatory excellence as key growth drivers for the next phase of India's pharma expansion
Collaboration aims to accelerate medicinal chemistry decision-making, reduce synthesis burden and strengthen data-secure AI adoption in drug discovery
Tomoyuki Hasegawa has been appointed CEO of FUJIFILM Biotechnologies California
Amitabh Dube and Sheetal Arora named Co-Chairmen for the forthcoming term
Ranluspec is the only interchangeable ranibizumab biosimilar approved in the United States in both vial and pre-filled syringe (PFS) presentations
Industry body aims to strengthen policy advocacy, innovation, and global competitiveness of India's fast-growing CRDMO sector
Dr. Rishi brings more than 15 years of experience in bioprocess development, microbial fermentation, technology transfer, and biotechnology operations
Anti-GD2 monoclonal antibody for high-risk neuroblastoma advances toward BLA submission following successful tech transfer from California to Bengaluru
We have the chance to build an IP estate that goes hand in hand with our generic pharmaceutical strength and build proprietary biological platforms
Subscribe To Our Newsletter & Stay Updated
